June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Real-world outcomes of anti-VEGF therapy: psychological, social and behavioral factors measured by the ALBATROS data collection instrument BPZ-9.
Author Affiliations & Notes
  • Christian Wolfram
    Ophthalmology, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Hamburg, Germany
    Johannes Gutenberg Universitat Universitatsmedizin Medizinische Klinik und Poliklinik I, Mainz, Rheinland-Pfalz, Germany
  • Norbert Pfeiffer
    Johannes Gutenberg Universitat Universitatsmedizin Medizinische Klinik und Poliklinik I, Mainz, Rheinland-Pfalz, Germany
  • Tobias Hudde
    Eye Hospital Wolfsburg-Fallersleben, Germany
  • Alexander Klatt
    Eye Center Klatt, Germany
  • Birthe Schnegelsberg
    Novartis Pharma Nuernberg, Germany
  • Heven Midani-Oezkan
    Novartis Pharma Nuernberg, Germany
  • Focke Ziemssen
    Universitatsklinikum Leipzig, Leipzig, Sachsen, Germany
  • Alexander Karl-Georg Schuster
    Johannes Gutenberg Universitat Universitatsmedizin Medizinische Klinik und Poliklinik I, Mainz, Rheinland-Pfalz, Germany
  • Footnotes
    Commercial Relationships   Christian Wolfram Novartis, Code F (Financial Support); Norbert Pfeiffer Novartis, Code F (Financial Support); Tobias Hudde Novartis, Code F (Financial Support); Alexander Klatt Novartis, Code F (Financial Support); Birthe Schnegelsberg Novartis, Code E (Employment); Heven Midani-Oezkan Novartis, Code E (Employment); Focke Ziemssen Novartis, Code F (Financial Support); Alexander Schuster Novartis, Code F (Financial Support)
  • Footnotes
    Support  Novartis Pharma
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 4224 – A0152. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christian Wolfram, Norbert Pfeiffer, Tobias Hudde, Alexander Klatt, Birthe Schnegelsberg, Heven Midani-Oezkan, Focke Ziemssen, Alexander Karl-Georg Schuster; Real-world outcomes of anti-VEGF therapy: psychological, social and behavioral factors measured by the ALBATROS data collection instrument BPZ-9.. Invest. Ophthalmol. Vis. Sci. 2022;63(7):4224 – A0152.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ophthalmic questionnaires (e.g. NEI-VFQ-25) are validated to assess quality of life (QoL) in retinal diseases including neovascular age related macular degeneration (nAMD), diabetic macular edema (DME) or branch-/central retinal vein occlusion (B/CRVO). They do not thoroughly assess the patients' social and psychological status. We present the new BPZ-9, a novel, exploratory questionnaire which intends to capture a more comprehensive view on the patients' situation.

Methods : The BPZ-9 instrument consists of 9 questions which assess patient dependency and wellbeing in terms of requirement for domestic care, walking difficulties, accompanying person necessary, anxiety about visual impairment or their disease or treatment, satisfaction with treatment, information provided and eye examinations, evaluated at baseline.

Results : The BPZ-9 questionnaire was completed at 102 sites. No patient had previously received anti-VEGF injections. Data was collected from 1444 nAMD (mean 78 years), 445 DME (67 y), 233 BRVO (70 y) and 144 CRVO (71 y) patients. 27% of patients had walking difficulties, ranging from 18% (BRVO) to 29% in nAMD (DME 24%, CRVO 22%). 12-23% of patients needed an accompanying person (23% nAMD, 21% DME, 12% BRVO, 19% CRVO). Most patients reported anxiety concerning visual impairment: 77% of nAMD patients, 73% DME, 73% CRVO and 60% of BRVO patients. Concern about their disease or treatment was mixed: while 32% and 44% of nAMD patients were very/moderately distressed, distress about treatment and disease control was lower (11% very, 34% moderately distressed). Within the DME, BRVO and CRVO groups a lower proportion of patients was very distressed by the disease (26%,24%, 23%), the majority was “moderately distressed” (42%,47%, 42%). Concern about treatment and controls was at the same level compared to nAMD patients. Overall, most patients were very satisfied with their treatment (73%) and felt very well informed (81%).

Conclusions : When patients with retinal disease initially require anti-VEGF therapy, they might face impaired mobility, dependency on others, distress and anxiety about their retinal condition and therapy. These factors may lead to social and psychological concerns influencing their behavior and attitude towards their disease. More research on patient psychology, attitude and impairments in treatment outcome is needed.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×